Evolus, Inc. (NASDAQ:EOLS) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Evolus, Inc. has received an average analyst rating of "Moderate Buy", with four firms rating it as a buy and one as a hold, reflecting positive sentiment towards the company's future prospects.
• The average 12-month price target for Evolus shares is currently set at $21.25, though analysts have recently adjusted their forecasts downward with some targets as low as $18.00.
• Recent insider activity includes a significant purchase by Director Brady Stewart of 30,000 shares at $6.82 each, indicating confidence in the company's direction.

Shares of Evolus, Inc. (NASDAQ:EOLS - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $21.25.

EOLS has been the topic of a number of recent analyst reports. Wall Street Zen cut Evolus from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. HC Wainwright decreased their target price on Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. BTIG Research lowered their price target on Evolus from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Finally, Needham & Company LLC restated a "hold" rating and issued a $22.00 price target on shares of Evolus in a research note on Wednesday, August 6th.

Evolus Trading Down 1.7%

NASDAQ:EOLS opened at $7.50 on Wednesday. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.27 and a quick ratio of 1.86. The firm has a market capitalization of $485.10 million, a price-to-earnings ratio of -7.65 and a beta of 1.07. Evolus has a one year low of $5.71 and a one year high of $17.82. The business has a fifty day moving average price of $8.36 and a 200-day moving average price of $10.31.

Insider Activity at Evolus

In related news, Director Brady Stewart bought 30,000 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was bought at an average cost of $6.82 per share, with a total value of $204,600.00. Following the completion of the purchase, the director owned 88,629 shares of the company's stock, valued at approximately $604,449.78. The trade was a 51.17% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of Evolus stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $7.51, for a total transaction of $42,972.22. Following the completion of the sale, the chief marketing officer owned 89,949 shares in the company, valued at approximately $675,516.99. This represents a 5.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 133,627 shares of company stock worth $1,325,764 in the last three months. Insiders own 6.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Manchester Capital Management LLC bought a new stake in Evolus in the second quarter worth $26,000. AlphaQuest LLC purchased a new position in shares of Evolus in the 1st quarter worth $39,000. State of Wyoming grew its stake in shares of Evolus by 988.1% in the 1st quarter. State of Wyoming now owns 3,754 shares of the company's stock worth $45,000 after buying an additional 3,409 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Evolus by 340.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company's stock worth $68,000 after buying an additional 5,691 shares during the last quarter. Finally, Profund Advisors LLC purchased a new stake in shares of Evolus during the 2nd quarter valued at about $100,000. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.